IVIg-induced acute polyneuroradiculitis in a patient with CIDP?
Krasenbrink
I
I
Kaps
M
M
Blaes
F
F
D000208:Acute Disease; D000368:Aged; D017809:Fatal Outcome; D005260:Female; D020275:Guillain-Barre Syndrome / Q000139:chemically induced* / Q000276:immunology / Q000503:physiopathology; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000009:adverse effects*; D007866:Leg / Q000294:innervation / Q000503:physiopathology; D018908:Muscle Weakness / Q000209:etiology / Q000503:physiopathology; D010291:Paresis / Q000209:etiology / Q000503:physiopathology; D010292:Paresthesia / Q000209:etiology / Q000503:physiopathology; D010956:Plasmapheresis; D018410:Pneumonia, Bacterial / Q000150:complications; D020277:Polyradiculoneuropathy, Chronic Inflammatory Demyelinating / Q000188:drug therapy* / Q000276:immunology / Q000503:physiopathology; D011782:Quadriplegia / Q000139:chemically induced; D012131:Respiratory Insufficiency / Q000139:chemically induced; D018805:Sepsis / Q000382:microbiology; D020886:Somatosensory Disorders / Q000209:etiology / Q000503:physiopathology; D013256:Steroids / Q000627:therapeutic use
D016756:Immunoglobulins, Intravenous; D013256:Steroids